Treatment|Cancer · June 3, 2026
FDA Approves New Oral Dissolving Drug for Chronic Myeloid Leukemia Patients
FDA approval of a new orally disintegrating tablet offers chronic myeloid leukemia patients greater flexibility in treatment optio...
Treatment · June 2, 2026
New Nilotinib Formulation Offers Flexible Dosing for CML Patients
FDA approval of a new orally disintegrating tablet formulation offers patients greater treatment flexibility for chronic myeloid l...